Premium
Transmission of Human Immunodeficiency Virus Type 1 by Dry‐Heated Clotting Factor Concentrates 1
Author(s) -
Dietrich S. L.,
Mosley J. W.,
Lusher J. M.,
Hilgartner M. W.,
Operskalski E. A.,
Habel L.,
Aledort L. M.,
Gjerset G. F.,
Koerper M. A.,
Lewis B. H.,
Pegelow C. H.
Publication year - 1990
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1990.tb00846.x
Subject(s) - clotting factor , medicine , human immunodeficiency virus (hiv) , serology , factor ix , virology , transmission (telecommunications) , limiting , antibody , immunology , virus , risk factor , viral disease , mechanical engineering , electrical engineering , engineering
. The Transfusion Safety Study monitored susceptible persons for human immunodeficiency virus type 1 (HIV‐1) infections transmitted by plasma products and blood components. Through December, 1988, 6 subjects without antibody to HIV‐1 (anti‐HIV‐1) became seropositive after receiving dry‐heated factor VIII concentrate. The preparations implicated in 3 cases were derived entirely from anti‐HIV‐1‐screened donors. In all instances, HIV‐1 infection could be explained by concentrates heated at 60 °C for 24–30 h. Limiting consideration to concentrates and components administered after study entry showed that 4 of the seroconversions occurred among 122 subjects given 10 million units of factor VIII concentrates. No seroconversions occurred among 84 subjects given 5 million units of factor IX concentrates, or 83 who received components from over 26,000 unpaid donations. Serologic surveillance of anti‐HIV‐1‐negative subjects provides important information, and should be routine in the management of persons receiving clotting factor concentrates.